While IFNγ and the IL‐17/IL‐23 axis are well established in psoriasis [87], IL‐4 has been shown to downregulate IL‐1β and IL‐6 production by psoriatic cells and may aid in psoriasis resolution, as observed during treatment with vitamin D3 analogues [88]. Here, IL17A is linked to psoriasis.